All In Biotech

Drug Trial Radar · NCT01453205

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL

Last checked: Nov 20, 2026Latest source record: Mar 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

187

Actual

Start

Feb 27, 2012

Primary completion

Jul 11, 2016

Study completion Jul 11, 2016

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 17, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • MEDI-551 2 mg/kgDrug

    MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).

  • RituximabDrug

    Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).

  • ICEDrug

    ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.

  • DHAPDrug

    DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.

  • Autologous Stem Cell Transplant (ASCT)Procedure

    Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.

  • MEDI-551 4 mg/kgDrug

    MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

Locations

81 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Burbank, California

  • Research Site

    Palm Springs, California

  • Research Site

    Sylmar, California

  • Research Site

    Atlanta, Georgia

  • Research Site

    Westwood, Kansas

  • Research Site

    Hazard, Kentucky

  • Research Site

    Lafayette, Louisiana

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Rochester, Minnesota

  • Research Site

    Kansas City, Missouri

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    The Bronx, New York

  • Research Site

    Fargo, North Dakota

  • Research Site

    Dayton, Ohio

  • Research Site

    Newark, Ohio

  • Research Site

    Sylvania, Ohio

  • Research Site

    Hershey, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Lubbock, Texas

  • Research Site

    Morgantown, West Virginia

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Saint John, New Brunswick, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Greenfield Park, Quebec, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Bordeaux, France

  • Research Site

    Le Mans, France

  • Research Site

    Libourne, France

  • Research Site

    Marseille, France

  • Research Site

    Marseille, France

  • Research Site

    Pessac, France

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.